- Home
- KPTI
as 05-20-2024 11:32am EST
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | NEWTON |
| Market Cap: | 133.0M | IPO Year: | 2013 |
| Target Price: | $4.80 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.62 - $2.67 | Next Earning Date: | 05-08-2024 |
| Revenue: | $140,461,000 | Revenue Growth: | -5.16% |
| Revenue Growth (this year): | 2.34% | Revenue Growth (next year): | 12.44% |
Share on Social Networks:
Stock Insider Trading Activity of Karyopharm Therapeutics Inc. (KPTI)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Paulson Richard A. | KPTI | President and CEO | May 6 '24 | Sell | $1.13 | 3,576 | $4,040.88 | 1,153,697 | SEC Form 4 |
| Paulson Richard A. | KPTI | President and CEO | Apr 4 '24 | Sell | $1.29 | 3,563 | $4,596.27 | 1,157,273 | SEC Form 4 |
| Poulton Stuart | KPTI | EVP, Chief Development Officer | Feb 29 '24 | Sell | $1.17 | 16,311 | $19,083.87 | 335,666 | SEC Form 4 |
| Poulton Stuart | KPTI | EVP, Chief Development Officer | Feb 29 '24 | Sell | $1.20 | 6,155 | $7,386.00 | 329,511 | SEC Form 4 |
| Cheng Sohanya Roshan | KPTI | EVP & Chief Commercial Officer | Feb 29 '24 | Sell | $1.17 | 21,840 | $25,552.80 | 398,618 | SEC Form 4 |
| Cheng Sohanya Roshan | KPTI | EVP & Chief Commercial Officer | Feb 29 '24 | Sell | $1.20 | 5,109 | $6,130.80 | 393,509 | SEC Form 4 |
| Paulson Richard A. | KPTI | President and CEO | Feb 29 '24 | Sell | $1.17 | 80,470 | $94,149.90 | 1,183,783 | SEC Form 4 |
| Paulson Richard A. | KPTI | President and CEO | Feb 29 '24 | Sell | $1.20 | 19,374 | $23,248.80 | 1,164,409 | SEC Form 4 |
| Mason Michael | KPTI | EVP, CFO & Treasurer | Feb 29 '24 | Sell | $1.17 | 27,687 | $32,393.79 | 404,918 | SEC Form 4 |
| Mason Michael | KPTI | EVP, CFO & Treasurer | Feb 29 '24 | Sell | $1.20 | 6,162 | $7,394.40 | 398,756 | SEC Form 4 |
| Mano Michael | KPTI | SVP, General Counsel&Secretary | Feb 29 '24 | Sell | $1.17 | 16,973 | $19,858.41 | 281,428 | SEC Form 4 |
| Mano Michael | KPTI | SVP, General Counsel&Secretary | Feb 29 '24 | Sell | $1.20 | 3,576 | $4,291.20 | 277,852 | SEC Form 4 |
| Mason Michael | KPTI | EVP, CFO & Treasurer | Feb 6 '24 | Sell | $1.59 | 4,205 | $6,671.23 | 246,945 | SEC Form 4 |
| Paulson Richard A. | KPTI | President and CEO | Feb 6 '24 | Sell | $1.59 | 4,012 | $6,365.04 | 821,453 | SEC Form 4 |
| Paulson Richard A. | KPTI | President and CEO | Jan 4 '24 | Sell | $0.82 | 4,114 | $3,373.48 | 783,465 | SEC Form 4 |
| Paulson Richard A. | KPTI | President and CEO | Dec 4 '23 | Sell | $0.79 | 3,622 | $2,861.38 | 787,579 | SEC Form 4 |
| Paulson Richard A. | KPTI | President and CEO | Nov 6 '23 | Sell | $0.92 | 3,606 | $3,318.60 | 791,201 | SEC Form 4 |
Latest Karyopharm Therapeutics Inc. News
KPTI Breaking Stock News: Dive into KPTI Ticker-Specific Updates for Smart Investing
Simply Wall St.
10 days ago
Karyopharm Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Insider Monkey
11 days ago
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call Transcript
GuruFocus.com
11 days ago
Karyopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
Thomson Reuters StreetEvents
12 days ago
Q1 2024 Karyopharm Therapeutics Inc Earnings Call
Motley Fool
12 days ago
Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Call Transcript
PR Newswire
12 days ago
Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference
GuruFocus.com
12 days ago
Karyopharm Therapeutics Reports Q1 2024 Financial Results: A Detailed Review
Associated Press Finance
12 days ago